Ultragenyx Pharmaceutical (RARE) Competitors $29.47 +1.34 (+4.76%) Closing price 04:00 PM EasternExtended Trading$29.84 +0.38 (+1.27%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RARE vs. QGEN, BBIO, ROIV, MRNA, ELAN, VRNA, RVMD, GRFS, ABVX, and RYTMShould you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include QIAGEN (QGEN), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Grifols (GRFS), Abivax (ABVX), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Ultragenyx Pharmaceutical vs. Its Competitors QIAGEN BridgeBio Pharma Roivant Sciences Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Revolution Medicines Grifols Abivax Rhythm Pharmaceuticals Ultragenyx Pharmaceutical (NASDAQ:RARE) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership. Is RARE or QGEN more profitable? Qiagen has a net margin of 18.30% compared to Ultragenyx Pharmaceutical's net margin of -87.34%. Qiagen's return on equity of 14.77% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Ultragenyx Pharmaceutical-87.34% -237.48% -37.66% Qiagen 18.30%14.77%8.87% Which has more volatility and risk, RARE or QGEN? Ultragenyx Pharmaceutical has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Which has better earnings & valuation, RARE or QGEN? Qiagen has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUltragenyx Pharmaceutical$560.23M5.08-$569.18M-$5.53-5.34Qiagen$2.04B4.99$83.59M$1.6927.08 Do analysts recommend RARE or QGEN? Ultragenyx Pharmaceutical currently has a consensus price target of $81.50, indicating a potential upside of 176.22%. Qiagen has a consensus price target of $49.69, indicating a potential upside of 8.58%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, equities analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92Qiagen 0 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.27 Do institutionals and insiders have more ownership in RARE or QGEN? 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to RARE or QGEN? In the previous week, Ultragenyx Pharmaceutical had 2 more articles in the media than Qiagen. MarketBeat recorded 8 mentions for Ultragenyx Pharmaceutical and 6 mentions for Qiagen. Ultragenyx Pharmaceutical's average media sentiment score of 1.08 beat Qiagen's score of 1.05 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryQiagen beats Ultragenyx Pharmaceutical on 9 of the 16 factors compared between the two stocks. Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RARE vs. The Competition Export to ExcelMetricUltragenyx PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.83B$3.18B$5.81B$10.49BDividend YieldN/A2.36%5.61%4.57%P/E Ratio-5.3121.25350.1526.89Price / Sales5.08412.26522.13164.64Price / CashN/A44.8326.0131.15Price / Book10.699.8415.496.51Net Income-$569.18M-$52.91M$3.30B$271.42M7 Day Performance1.74%3.65%200.89%3.65%1 Month Performance-0.92%5.54%184.42%8.03%1 Year Performance-49.78%13.40%325.52%29.81% Ultragenyx Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAREUltragenyx Pharmaceutical4.3837 of 5 stars$29.47+4.8%$81.50+176.6%-52.1%$2.84B$560.23M-5.331,294Positive NewsQGENQIAGEN4.4329 of 5 stars$45.39+0.2%$49.69+9.5%+5.3%$10.09B$1.98B26.825,765Positive NewsBBIOBridgeBio Pharma4.3844 of 5 stars$51.47+0.5%$63.94+24.2%+95.8%$9.84B$221.90M-12.58400ROIVRoivant Sciences3.4333 of 5 stars$13.95-0.9%$17.67+26.6%+25.6%$9.53B$29.05M-19.93860Positive NewsAnalyst RevisionMRNAModerna4.4639 of 5 stars$23.88+1.6%$41.81+75.1%-61.6%$9.29B$3.24B-3.175,800ELANElanco Animal Health2.793 of 5 stars$18.63+0.5%$17.33-6.9%+36.3%$9.25B$4.44B21.669,000VRNAVerona Pharma PLC American Depositary Share2.0527 of 5 stars$106.37-0.1%$109.00+2.5%+253.5%$9.17B$42.28M-107.4430Positive NewsRVMDRevolution Medicines4.2654 of 5 stars$46.20-0.8%$73.67+59.5%-4.1%$8.64B$11.58M-10.27250GRFSGrifols3.9711 of 5 stars$9.63-2.5%$10.30+7.0%+8.8%$6.62B$7.45B8.2323,822Positive NewsABVXAbivax2.5474 of 5 stars$85.87+2.2%$99.43+15.8%+628.3%$6.49BN/A0.0061RYTMRhythm Pharmaceuticals3.102 of 5 stars$96.03-0.2%$101.57+5.8%+81.9%$6.38B$130.13M-31.90140Positive News Related Companies and Tools Related Companies QIAGEN Alternatives BridgeBio Pharma Alternatives Roivant Sciences Alternatives Moderna Alternatives Elanco Animal Health Alternatives Verona Pharma PLC American Depositary Share Alternatives Revolution Medicines Alternatives Grifols Alternatives Abivax Alternatives Rhythm Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RARE) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RARE Stock Alerts